West Mining Semi-Annual Financial Report Analysis

Revenue grew by 25%, and profit surged by 123%—meaning that each additional RMB of revenue translated into a disproportionately larger increase in profit. This is the most compelling 'operating leverage' effect seen during commodity price-up cycles in mining companies. The drivers are threefold: 1. Price: Significant product price increases—Shanghai copper average price at RMB 102,000/ton (up 31% YoY), molybdenum concentrate (+28%), zinc (+5%), gold (+43.7%), silver (+139%). 2. Cost: Relatively fixed costs—nearly all price gains flowed directly to profit. 3. Recovery rate improvement: Copper and molybdenum recovery rates at Yulong Copper Mine’s Workshop I rose by 2.41 and 9.41 percentage points, respectively. All product lines delivered robust profitability: Product Output YoY Change Plan Achievement Rate Avg. Price YoY Copper (mine-produced) 89,700 tons –2% 106% +31% Zinc (mine-produced) 63,900 tons +2% 102% +5% Lead (mine-produced) 29,500 tons –16% 96% –2% Molybdenum (mine-produced) 2,368 tons –6% 109% +28% Copper (smelted) 164,000 tons –10% 106% — Sulfuric acid 417,400 tons — — +162% Source: Yulong Copper Mine—the absolute "profit engine": ・ Yulong Copper Co., Ltd., in which West Mining holds a 58% stake, posted net profit of RMB 5.059 billion in H1, achieving an exceptional net margin of 60%. ・ At its 58% ownership stake, it contributed approximately RMB 2.93 billion in attributable net profit—accounting for 70% of West Mining’s consolidated net profit. ・ Yulong produced 82,400 tons of copper, representing 92% of West Mining’s total mine-produced copper output. Smelting segment achieved historic turnaround: All three major smelting businesses—copper, lead, and zinc—turned profitable, collectively contributing RMB 595 million in profit. Two previously loss-making subsidiaries—Qinghai Copper Co., Ltd. and Rare & Precious Metals Co., Ltd.—both returned to profitability in 2025. Step Two: Cash Collection Capability (Net Operating Cash Flow to Net Profit Ratio)—Exceptional Indicator H1 2026 H1 2025 Net operating cash flow RMB 8.349 billion RMB 5.010 billion Consolidated net profit RMB 4.169 billion RMB 1.869 billion Net operating cash flow to net profit ratio ~2.00x ~2.68x Source: Assessment: A net operating cash flow to net profit ratio of ~2x means every RMB of profit is backed by RMB 2 of actual cash—indicating exceptionally high earnings quality. Net cash outflow from financing activities totaled RMB 3.776 billion, reflecting the company’s proactive debt reduction and deleveraging efforts. Step Three: Balance Sheet—Significant Deleveraging Indicator H1 2026 Beginning / YoY Change Asset-liability ratio 53.72% 57.50% (end of prior year) –3.78 ppts Consolidated net assets RMB 22.42 billion — +22% (vs. beginning of year) EBITDA interest coverage ratio 30.77x 18.31x +12.46x Source: Assessment: Asset-liability ratio declined from 57.50% to 53.72%, down 5.25 percentage points YoY. EBITDA interest coverage ratio surged from 18.31x to 30.77x, indicating extremely strong debt-servicing capacity. Net cash outflow from financing activities amounted to RMB 3.776 billion, confirming active debt repayment and deleveraging. However, the interest-bearing debt-to-asset ratio has reached 39.88%, warranting continued attention to debt structure.

Thermo Fisher Scientific Q2 2023 Financial Report: Total Revenue Down 3%; Weakness in Chinese Market Reduced One-Third of Revenue

As the saying goes, 'Cold or warm water upstream is felt first downstream.' The latest financial report from Thermo Fisher Scientific—a global leader in life sciences tools and laboratory automation—offers fresh insight into the evolving dynamics of China’s biopharmaceutical market. On July 26, Thermo Fisher Scientific released its Q2 2023 results: second-quarter revenue totaled USD 10.69 billion, down 3% YoY from USD 10.97 billion; net income was USD 1.362 billion, down 18% YoY from USD 1.668 billion. During Wednesday’s investor conference call, CEO Marc Casper stated that the revenue decline stemmed from 'a more challenging macroeconomic environment this quarter.' CFO Stephen Williamson added that one-third of the core revenue decline was attributable to reduced economic activity in China, while other customers—including biotech firms—cut spending. In Q2 2023, Thermo Fisher’s GAAP diluted EPS was USD 3.51, down from USD 4.22 in the prior-year period; GAAP operating profit was USD 1.58 billion, versus USD 2.0 billion a year earlier; and GAAP operating margin stood at 14.8%, compared to 18.2% in Q2 2022. By business segment, Life Sciences Solutions generated USD 2.463 billion in Q2 2023 revenue—representing 23% of total revenue—down from USD 3.292 billion in the prior-year quarter. The Analytical Instruments segment reported Q2 2023 revenue of USD 1.749 billion—16.4% of total revenue—versus USD 1.607 billion in the prior-year quarter.

Minerals Technologies Schedules Q2 Results Call for July 31 After July 30 Close

Jul 2, 2026

Minerals Technologies Inc plans to release its second-quarter 2026 results after market close on July 30, 2026. Investors will join a conference call on July 31, 2026, at 11 a.m. ET to discuss the findings.

Stock Titan

2026-04-30

Minerals Technologies Inc. Announces 2026 First Quarter Financial Results

2026-04-30

Minerals Technologies Inc. Reports Q1 Adjusted EPS of $1.38, Beating Estimates

2026-04-30

Minerals Technologies: Q1 Earnings Snapshot

2026-04-30

Minerals Technologies Inc. Reports Q1 Revenue of $546.9 Million, Beating Estimates

2026-05-01

Sales reach $547M as Minerals Technologies posts 21% EPS gain